GH1 and cardiomyopathy: In conclusion, consistent with our analysis, previous studies and evidence have preliminarily suggested that GH could be a potential clinical biomarker or therapeutic direction for cardiomyopathy and HF, but more studies are needed to confirm these suggestions urgently.